Autopsy report · NCT05163717

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Busness reason's”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months before it started.
Ran for about 10 months before it stopped.
8 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Impel Pharmaceuticals
Sponsor type: Industry
Conditions: Agitation in Adolescents and Young Adults With ASD
Interventions: INP105; Placebo
Participants: 8
Sites: 2
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.